Insider Shareholders with Direct Ownership of Arbutus Biopharma Corp (ABUS)
This section provides a comprehensive overview of the insiders with direct ownership of Arbutus Biopharma Corp (ABUS). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Arbutus Biopharma Corp Insider List
Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
---|---|---|---|---|---|
Roivant Sciences Ltd.
> 10% Shareholder |
22,833,922 | 0 | 38,847,462 $133 Million | 1 |
Oct 18, 2021
Added 37.02%
|
Michael J. Mc Elhaugh
Interim President & CEO |
384,500 | 93,954 | 1,658,003 $5.67 Million | 7 |
Feb 14, 2025
Added 9.65%
|
Michael J. Sofia
Chief Scientific Officer |
191,700 | 209,982 | 1,485,121 $5.08 Million | 4 |
Feb 02, 2024
Reduced 0.67%
|
David C Hastings
Chief Financial Officer |
281,600 | 31,776 | 249,824 $854,398 | 5 |
Feb 14, 2025
Added 26.51%
|
William H. Collier
President and CEO |
216,500 | 0 | 216,500 $740,430 | 1 |
Feb 01, 2023
Added 50.0%
|
Karen Sims
Chief Medical Officer |
150,300 | 23,706 | 155,494 $531,789 | 4 |
Feb 14, 2025
Added 24.07%
|
J. Christopher Naftzger
General Counsel and CCO |
149,400 | 11,333 | 140,544 $480,660 | 3 |
Feb 14, 2025
Added 27.87%
|
Elizabeth Howard
EVP, GC, Compliance |
69,700 | 0 | 86,024 $294,202 | 1 |
Feb 01, 2023
Added 44.76%
|
Keith S Manchester
Director |
54,915 | 8,846 | 46,069 $157,555 | 2 |
Aug 14, 2024
Reduced 16.11%
|